Author/Authors :
Bièche، نويسنده , , Roberto N. Onody، نويسنده , , P and Lerebours، نويسنده , , F and Tozlu، نويسنده , , S and Hacene، نويسنده , , K and Andrieu، نويسنده , , C and Vidaud، نويسنده , , M and Tubiana-Hulin، نويسنده , , M and Spyratos، نويسنده , , R. Lidereau، نويسنده , , R، نويسنده ,
Abstract :
We examined the relation between ERBB2 gene expression (as determined by a real-time quantitative RT-PCR assay) and the response to adjuvant tamoxifen therapy in a well-defined cohort of 125 ERα-positive postmenopausal patients with breast cancer. Although ERBB2 overexpression was associated with shorter relapse-free survival in univariate analysis (P=0.00029), ERBB2 did not persist as an independent prognostic factor in multivariate analysis. Nevertheless, when we analyzed the ERBB2 mRNA level as a continuous variable, the higher the ERBB2RNA level, the poorer the outcome (P=0.00036). The results point to the need for a quantitative ERBB2 expression assay for use in future studies of ERBB2-based clinical management of breast cancer.
Keywords :
ER?-positive postmenopausal breast cancer , erbB2 , Real-time RT-PCR quantification , Endocrine therapy
